A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).
Copy For Citation
Abali H., Yalcin S., Onal H. C., Dane F., Oksuzoglu B., Ozdemir N., ...More
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 21 - 23 January 2016, vol.34
-
Publication Type:
Conference Paper / Summary Text
-
Volume:
34
-
Doi Number:
10.1200/jco.2016.34.4_suppl.tps182
-
City:
San-Francisco
-
Country:
Costa Rica
-
Hacettepe University Affiliated:
Yes